This study is intended to estimate the absolute bioavailability of Glasdegib by comparison of
the pharmacokinetic exposures following administration of an oral, single dose 100 mg tablet
vs. an IV infusion of a 50 mg IV dose in the fasted state in a crossover fashion to healthy
volunteers.